Australian Institute of Health and Welfare (2022) Medication use for secondary prevention after coronary heart disease hospitalisations: Patient pathways using linked data, AIHW, Australian Government, accessed 25 April 2024. doi:10.25816/hm5d-s745
Australian Institute of Health and Welfare. (2022). Medication use for secondary prevention after coronary heart disease hospitalisations: Patient pathways using linked data. Canberra: AIHW. doi:10.25816/hm5d-s745
Australian Institute of Health and Welfare. Medication use for secondary prevention after coronary heart disease hospitalisations: Patient pathways using linked data. AIHW, 2022. doi:10.25816/hm5d-s745
Australian Institute of Health and Welfare. Medication use for secondary prevention after coronary heart disease hospitalisations: Patient pathways using linked data. Canberra: AIHW; 2022. doi:10.25816/hm5d-s745
Australian Institute of Health and Welfare 2022, Medication use for secondary prevention after coronary heart disease hospitalisations: Patient pathways using linked data, AIHW, Canberra. doi:10.25816/hm5d-s745
PDF | 2.7Mb
This project used the National Integrated Health Services Information Analysis Asset to explore factors that affect medication use among 67,800 people who were hospitalised for coronary heart disease. It found that younger patients and women were among those people less likely to be dispensed cardiovascular medicines and to still be taking them 1 year after leaving hospital. This information may inform strategies to improve medication use among these groups.
61% of people with acute coronary syndrome initiated ≥3 of the 4 classes of CVD medicines within 40 days of discharge
Women and people aged under 65 were less likely to be dispensed the recommended medicines following hospitalisation
3 in 4 patients were still taking their medicines 1 year after leaving hospital
Contact with community-based health care services was associated with use of recommended CVD medicines
In the technical report, the description of the Pharmaceutical Benefits Scheme (PBS) has been updated from 'dispensed medicines that are partially or fully funded by the Australian Government' to 'dispensed medicines that are subsidised by the Australian Government. Patients' concessional status determines which co-payment they pay for their PBS/RPBS prescriptions'.
